Nashua, NH: Eagle Biosciences announces the product launch of a new Recombinant Human Insulin Biotin-labeled (Biotinylated Insulin). The Recombinant Human Insulin was developed by ibt – Immunological and Biochemical Testsystems GmbH using their exceptional biotinylation technology. This technology is unlike others in the market because it permits biotinylation without loss of activity and is designed specifically for Insulin, IGFs and analogs. This protein is offered in a lyophilized form which not only increases overall activity but also enhances stability.
This Recombinant Human Insulin was developed for use in numerous applications such as ELISA, FACS, MACS, ligand blotting, cross-linking studies, receptor binding, isolation, antigen processing experiments, clearance studies, cell therapy, tissue engineering, ligand blotting, immunohistochemistry, flow cytometry, and many other methods/techniques. It is a great addition to Eagle’s biotinylated protein product line which includes Recombinant Human IGFBP-2, IGFBP2, and IGFBP-6.
“The proteins offered in Eagle’s biotinylated protein product portfolio were the first commercially available.” said Dan Keefe, President of EagleBio, “And we continue to strive to bring interesting, esoteric products to our customers.” Keefe continued, “This protein meets and exceeds that criteria because it is not only one-of- kind in the market but also provide investigators the opportunity to apply it across multiple methods and areas of research.”
Eagle is offering promotional pricing for researchers measuring insulin (Recombinant Human Insulin, Biotin-labeled) through the next few months. This protein is currently for research use only. Check out the Eagle website www.EagleBio.com or call 866-411-8023 for full details.